ACT-660602

ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC50 value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research[1][2].

Product Specifications

CAS Number

[1646267-59-5]

UNSPSC

12352005

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/act-660602.html

Purity

99.02

Solubility

DMSO : 110 mg/mL (ultrasonic)

Smiles

FC(C1=NC=C(C2=C(N3C[C@@H](C)N(C(CN4N=C(C)N=C4C)=O)CC3)SC(C(F)(F)F)=N2)C=N1)(F)F

Molecular Formula

C20H20F6N8OS

Molecular Weight

534.48

References & Citations

[1]Meyer EA, et al. Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases. J Med Chem. 2022 Aug 10.|[2]Caroff Eva, et al. Preparation of piperazinyltriazolylethanone derivatives for use as CXCR3 receptor modulators: World Intellectual Property Organization, WO2015011099. 2015-01-29.